FDA ORIG Approval: ENLICITIDE — MERCK SHARP AND DOHME LLC (Not disclosed in the FDA record.)

Key facts

What was approved

FDA's record shows MERCK SHARP AND DOHME LLC as the sponsor of ENLICITIDE, with the generic name recorded as unspecified and dosage form TABLET. A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information. This specific application is submission type ORIG (submission number 1) under application number NDA220848, with a submission status date of 20260716. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. This record is drawn directly from FDA's own approvals database rather than from company press materials. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

Regulatory context

This application was reviewed under FDA's ORIG submission pathway. A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information. FDA approval of an application does not itself guarantee ongoing marketing; sponsors remain subject to post-approval manufacturing inspections and adverse-event reporting requirements. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

Merck Sharp & Dohme LLC’s FDA history

Argus HQ has recorded 3 total FDA actions tied to Merck Sharp & Dohme LLC: 0 warning letters, 2 recalls, 1 approval record, and 0 Form 483 inspection citations.

Frequently asked questions

What does the submission type mean?

A New Drug Application (NDA) is the FDA pathway used to approve a new drug product, typically requiring the sponsor to submit full preclinical and clinical evidence of safety and efficacy for the intended use, along with manufacturing and labeling information.

Is this product available now?

FDA's record lists a submission status date of 20260716. Availability, pricing, and distribution details beyond the submission status date are Not disclosed in the FDA record. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

Does MERCK SHARP AND DOHME LLC have other FDA approval records?

Yes. Argus HQ has recorded 3 total FDA actions tied to MERCK SHARP AND DOHME LLC, including 1 approval record.

What is the FDA application number for this submission?

FDA application number NDA220848, submission 1.

Related enforcement actions

• Recall: Merck Sharp & Dohme LLC — Class II recall: Noxafil Powdermix (posaconazole) for Delayed-Release Oral Suspension, 300 mg, 8… →
• Recall: Merck Sharp & Dohme LLC — Class II recall: Merck Emend (aprepitant) for oral suspension, 125 mg, Single-Dose Kit, Rx Only,… →